Nashville-based IQuity, a specialty diagnostics technology company, recently announced its technology, IQIsolate®, can detect the presence or absence of autoimmune and related conditions at the earliest sign of symptoms. By leveraging machine learning to analyze RNA expression data from patient blood samples, the company's academic research has produced results of greater than 90 percent accuracy across three medical specialties: neurology, gastroenterology and rheumatology.

When commercialized, clinical laboratory results will be returned to providers in only seven days. IQuity believes this technology will shorten the diagnostic process of complicated autoimmune diseases and related conditions. Additionally, within a medical discipline, the technology can distinguish between diseases that present with similar symptoms, such as Crohn's and ulcerative colitis in the gastroenterology panel.